Navigation Links
Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Date:2/12/2013

,308Operating expensesSelling and marketing 

12,693

10,89247,543

39,142Research and development3,192

2,83712,972

10,079General and administrative 

4,667

4,03016,278

15,109Total operating expenses20,552

17,75976,793

64,330Income (loss) from operations4,239

1,42812,133

(2,022)Interest income, net

21

860

125Other income (expense), net

223

(154)532

(201)Income (loss) before income taxes4,483

1,28212,725

(2,098)Income tax provision 

444

1991,764

807Net income (loss)$
4,039

$
,083$
,961

$
(2,905)Diluted net income (loss) per share 

$
.27

$
.08$
.79

$
(0.23)Diluted weighted average shares outstanding

15,101

12,84713,792

12,585Basic net income (loss) per share 

$
.28

$
.09$
.83

$
(0.23)Basic weighted average shares outstanding

14,555

12,56713,189

12,585 Condensed Consolidated Balance Sheet (Unaudited)(In thousands)December 31, 20122011Assets:Cash, cash equivalents and marketable securities

$
86,057$
35,694Short-term investments and related financial instruments

40,61731,379Accounts receivable, net17,97012,853Inventories32,90629,568Deferred tax asset, current portion703701Prepaid expenses and other current assets5,1493,038Total current assets183,402113,233Property and equipment, net8,2077,705Long-term marketable securities20,0716,595Goodwill and intangibles, net21,74823,486Other noncurrent assets667561Total assets$
234,095$
51,580Liabilities and stockholders' equity:Accounts payable and accrued expenses$
25,865$
22,418Amounts due to related parties1,8961,550Deferred revenue6,3196,388Capital lease obligations322239Total current liabilities34,40
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
2. Cynosure Announces Upcoming Conference Presentations
3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... such as primary biliary cirrhosis, today announced that ... Executive Officer, will present at the Deutsche Bank Securities ... on Wednesday, May 29, 2013 at 4:10 ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
... ... Study, Pharmacokinetic Study Demonstrates Lack of Systemic Exposure of XIAFLEX, ... Conference call scheduled for today, June 3, at 8:45 a.m. Eastern Time, ... positive top-line,efficacy and safety results from the CORD I and CORD II phase ...
... 2 Alliance,Pharmaceutical Corp. (OTC Bulletin Board: ALLP) announced ... the two proposals put to the,shareholders at its Annual ... first proposal related to the re-election of each of ... additional term of one year or,until their successors are ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting 2
(Date:5/23/2013)... The sodium theory has ... B. Katz in the early 1950s, after their experiments ... sodium and potassium ions in nerve functions . ... techniques have known amazing developments. In The Sodium Theory ... an account of the latest developments in the field ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Voyance, ... and perception management tools, and ASCA, the industry’s ... the new ASCA Benchmarking Program. Voyance ... technology and national benchmarking experience to support ASCA’s ... comprehensive, state-of-the-art benchmarking tool. , “Voyance is both ...
(Date:5/23/2013)... Park, FL (PRWEB) May 23, 2013 ... Day Belly Blast Diet to determine what makes this ... , The published review highlights three main components of ... rate; achieving a positive mindset and the personal motivation ... calorie intake every 7 days to keep the metabolism ...
(Date:5/23/2013)... eat at fast-food restaurants are consuming significantly more calories ... offenders, a new study found. "Teens underestimate the ... as 34 percent, parents of school-age children by as ... as 20 percent," study lead researcher, Dr. Jason Block, ... Johnson Foundation, which helped fund the study. ...
(Date:5/23/2013)... Susquehanna Health is now ... babysitting training course for adolescents age 11 and up. ... pediatrician Dr. Patricia Keener after a colleague’s toddler choked ... sitter who didn’t know how to provide first aid. ... a medical basis that aims to reduce the number ...
Breaking Medicine News(10 mins):Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 2Health News:Yves Pichon’s New Book Presents Latest Neurophysiological Discoveries 3Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 2Health News:Voyance and ASCA Announce Strategic Partnership to Better the ASC Industry 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3
... in Central Mexico who used a vented stove instead of ... par with a pack-a-day smoker kicking the habit, according to ... first year of data in an ongoing project examining the ... open fires, was reported in the October 1 issue of ...
... NEW YORK, Sept. 22 Preet Bharara, the U.S. Attorney ... Dowd, formerly the senior manager of human resources of Hitachi America ... 57 months in prison for defrauding the Hitachi America Group Health ... sentence was imposed by U.S. District Judge Colleen McMahon. Dowd pleaded ...
... ... bioidentical hormone replacement therapy and nutritional supplements in battle against the deadly disease ... Jacksonville, Fla. (Vocus) ... than five million people in the United States and 35 million people worldwide are ...
... , NEW YORK, Sept. 22 Assurant, Inc. ("Assurant") (NYSE: ... products and services, will release 2009 third quarter financial results on Wednesday, ... available on Assurant,s Web site at www.assurant.com . , ... conference call at 9:00 a.m. ET on Thursday, Oct. 29, 2009 with ...
... , , , , ... provide affordable health insurance for all, , , ... public or private , , Sixty-three percent favor ... A nationwide survey commissioned by the United States Conference of Catholic Bishops ...
... , , SCHAUMBURG, Ill., Sept. 22 ... Peter Beilenson, MD, MPH, announced they are introducing a regulation to ... of indoor tanning devices for all residents under the age of ... its kind in the nation. , , "The ...
Cached Medicine News:Health News:New stove dramatically improves lung health in Mexican women 2Health News:New stove dramatically improves lung health in Mexican women 3Health News:Former Corporate Benefits Manager Sentenced to 57 Months in Prison for Defrauding Health Care Plan of More Than $6 Million Dollars 2Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 2Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 3Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 4Health News:Report Finds Alzheimer's Killing More People Than Breast And Prostate Cancer Combined 5Health News:Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29 2Health News:New Survey: Most Americans Want Health Care Reform, Oppose Abortion Coverage, Support Conscience Protection Laws 2Health News:American Academy of Dermatology Association Commends Howard County for Proposing the Most Restrictive Indoor Tanning Regulation in the Country 2
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... H.pylori gII test is a lateral-flow immuno-chromatographic ... of IgG antibodies specific to Helicobacter pylori ... It utilizes a convenient, non-invasive, and easy ... in the diagnosis of H.pylori infection in ...
... HP is a visually read, qualitative immunochromatographic ... H. pylori, a bacterium that grows in ... ulcer disease and some gastric cancers. FlexSure ... blood or serum samples, provides the physician ...
Medicine Products: